At the least, the new 7.2mg results point to scope for hiking the semaglutide dose in CagriSema to chase down that weight-loss target. The company is also running a phase 3b trial of 7.2mg ...
Findings showed semaglutide 7.2mg demonstrated a statistically significant and superior weight loss compared with placebo at week 72. Topline data were announced from a phase 3b trial evaluating ...
Dyck and his team focused their research on Ozempic, a widely used weight-loss medication, to better understand its reported side effect of skeletal muscle loss. Ozempic, known medically as ...